The condition causes the stomach muscles to stop working properly, preventing food from moving into the small intestine at a normal rate and often resulting in severe abdominal pain
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 [6] (Wadden et al., Nat Med , 2023))
How Personalized Genetic Testing Optimizes Your GLP-1 Experience The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R, GIPR, and MC4R variants that relate to GLP-1 and related signaling pathways
Clinical Trials Semaglutide: The GLP-1 has shown potential, with approximately 15% of body weight lost
Specifically, PLB downregulated cytochrome C and ferritin, while upregulating TFAM and GPX4
Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs
